Cardiotoxicity of doxorubicin in a child with acute leukemia
- Authors: Cherezova I.N.1, Gabitova N.K.1, Osipova I.V.2
-
Affiliations:
- Kazan State Medical University
- Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
- Issue: Vol 31, No 7 (2024)
- Pages: 118-123
- Section: Clinical case
- URL: https://journals.eco-vector.com/2073-4034/article/view/646393
- DOI: https://doi.org/10.18565/pharmateca.2024.7.118-123
- ID: 646393
Cite item
Abstract
The introduction of innovative drug therapy regimens for blood cancers in children has increased life expectancy and event-free survival. An integral component of most modern antitumor therapy regimens used in pediatric oncology are anthracycline antibiotics, the effectiveness of which has been clinically proven. The use of drugs in this group is associated with the development of side effects, such as cardiotoxicity. Clinical manifestations of cardiotoxicity manifest as impaired myocardial contractile function and cardiomyopathy with congestive heart failure, arrhythmias and can lead to a reduction in life expectancy. The article presents a clinical case of cardiotoxicity of an anthracycline drug with the development of dilated cardiomyopathy and heart failure in a patient with acute lymphoblastic leukemia. Timely detection of clinical signs of cardiotoxicity and the use of cardioprotective therapy improved the prognosis of the disease and the patient’s quality of life.
Keywords
Full Text

About the authors
I. N. Cherezova
Kazan State Medical University
Author for correspondence.
Email: Borismk1@rambler.ru
ORCID iD: 0000-0001-8961-0996
Cand. Sci. (Med.), Associate Professor, Department of Hospital Pediatrics
Russian Federation, KazanN. Kh. Gabitova
Kazan State Medical University
Email: Borismk1@rambler.ru
ORCID iD: 0000-0002-8375-0565
Russian Federation, Kazan
I. V. Osipova
Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Email: Borismk1@rambler.ru
ORCID iD: 0000-0001-9833-5156
Russian Federation, Kazan
References
- ВОЗ. Рак. Информационный бюллетень. Февраль 2024 г. Социальные аспекты здоровья населения. 2024;1(70). [WHO. Cancer. News bulletin. February 2024. Social Aspects of Population Health. (In Russ.)]. URL: http://www.vestnik.mednet.ru
- Багиров И.А, Быданов О.И., Петина О.В. и др. Заболеваемость лимфобластным лейкозом детей в Азербайджанской Республике: эпидемиологические данные и сравнительный анализ. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2015;14(3):55–9. [Bagirov I.A., Bydanov O.I., Petina O.V., et al. Incidence of acute lymphoblastic leukemia in children in Azerbaijan Republic: Epidemiology and comparative analysis. Pediatric Hematology/Oncology and Immunopathology. 2015;14(3):55–59. (In Russ.)]. doi: 10.24287/1726-1708-2015-14-3-55-59.
- Чаулин А.М., Дупляков Д.В. Аритмогенные эффекты доксорубицина. Комплексные проблемы сердечно-сосудистых заболеваний. 2020;9(3):69–80. [Chaulin A.M., Duplakov D.V. Arrhythmogenic effects of doxorubicin. Compl Issues Cardiovasc Dis.2020; 9(3):69–80. (In Russ.)]. doi: 10.17802/2306-1278-2020-9-3-69-80.
- Кулева С.А., Семиглазова Т.Ю., Звягинцева Д.А. и др. Кардиоваскулярная токсичность противоопухолевого лечения у детей. Педиатрия. 2017;8(3):130–41. [Kulyova S.A., Semiglazova T.Yu., Zvyagintseva D.A., et al. Cardiovascular complications of antineoplastic therapy in children. Pediatr. (St Petersburg). 2017;8(3):130–41. (In Russ.)]. doi: 10.17816/PED83130-141.
- Kong C.Y., Guo Z., Song P., et al. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. Int. J. Biol. Sci. 2022;18(2):760–70.
- Kciuk M., Gielecinska A., Mujwar S., et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659.
- Калюта Т.Ю., Киселев А.Р., Базарбаева А.Х. Кардиотоксичность лекарственных препаратов: возможности профилактики и коррекции (обзор). Саратовский научно-медицинский журнал. 2020;16(3):736–43. [Kalyuta T.Yu., Kiselev A.R., Bazarbaeva A.Kh. Medication cardiotoxicity: potential of prevention and correction (review). Saratov J Med Sci Res. 2020;16(3):736–43. (In Russ.)].
- Curigliano G., Lenihan D., Fradley M., et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. doi: 10.1016/j.annonc.2019.10.023.
- Sobiborowicz-Sadowska A.M., Kaminska K., Cudnoch-Jedrzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers (Basel). 2023;15(1):312. doi: 10.3390/cancers15010312.
- Прус Ю.А., Сергиенко И.В., Кухарчук В.В., Фомин Д.К. Кардиотоксичность, индуцированная химиотерапией и лучевой терапией. Атеросклероз и дислипидемия. 2017;3:56–72.[Prus Yu.A., Sergienko I.V., Kukharchuk V.V., Fomin D.K. Cardiovascular toxicity induced by chemotherapy and radiotherapy. Atheroscler Dyslipid. 2017;3:56–72. (In Russ.)].
- Oikawa M., Ishida T., Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. J Cardiol. 2023;81(3):253–59.
- Яндиева Р.А., Сарибекян Э.К., Мамедов М.Н. Кардиотоксичность при лечении онкологических заболеваний. Международный журнал сердца и сосудистых заболеваний 2018;6(17):3–12. [Yandieva R.A., Saribekyan E.K., Mamedov M.N. Cardiotoxicity in the treatment of cancer. Int J Heart Vasc Dis. 2018;6(17):3–12. (In Russ.)].
- Канорский С.Г., Павловец В.П. Кар-диотоксичность антрациклинов и возможности ее коррекции. Южно-Российский журнал терапевтической практики. 2023;4(3):7–14. [Kanorskiy S.G., Pavlovets V.P. Codiotoxicity of anthraciclines and the possibilities of its correction. South Russ J Ther Pract. 2023;4(3):7–14. (In Russ.)]. doi: 10.21886/2712-8156-2023-4-3-7-14.
- Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и солидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127–36. [Kogoniya L.M., Rusanov M.O., Shikina V.E. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. Onkogematologiya. 2022;17(3):127–36. (In Russ.)]. doi: 10.17650/1818-8346-2022-17-3-127-136.
- Фашафша З.З., Меситская Д.Ф., Копылов Ф.Ю. и др. Диагностические аспекты сердечно-сосудистых осложнений химиотерапии. Кардиология и сердечно-сосудистая хирургия. 2022;15(1):40–5. [Fashafsha Z.Z., Mesitskaya D.F., Kopylov F.Yu., et al. Diagnostic aspects of cardiovascular complications following chemotherapy. Rus J Card Cardiovasc Surg. 2022;15(1):40–5. (In Russ.)]. doi: 10.17116/kardio20221501140.
- Синицкий М.Ю., Цепокина А.В., Хуторная М.В. и др. Генетические основы кардиотоксичности антрациклинов: обзор литературы. Acta Biomed. Sci. 2021;6(4):27–38. [Sinitsky M.Yu., Tsepokina A.V., Khutornaya M.V., et al. Genetic basis of anthracyclines cardiotoxicity: Literature review. Acta Biomed. Sci. 2021;6(4):27–38. (In Russ.)]. doi: 10.29413/ABS.2021-6.4.3.
- Suter T.M., Ewer M.S. Cancer drugs and the heart: Importance and management. Eur Heart J. 2013;34(15):1102–11. doi: 10.1093/eurheartj/ehs181.
- Матяш М.Г., Кравчук Т.Л., Высоцкая B.В. и др. Индуцированная антрациклиновая кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008;6(30):66–75. [Matyash M.G., Kravchuk T.L.,Vysotskaya V.V., et al. Anthracycline-induced cardiotoxicity: mechanisms of development and clinical manifestations. Siber J Oncol. 2008;6(30):66–75. (In Russ.)].
- Cardinale D., Iacopo F., Cipolla C.M. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. doi: 10.3389/fcvm.2020.00026.
- Перепечко Д.Д., Маль Г.С. Лекарственно индуцированная кадиотоксичность, ассоциированная с применением противоопухолевых антибиотиков. Кардиология: новости, мнения, обучение. 2021;9(1):32–8. [Perepechko D.D., Mal G.S. Drug-induced cardiotoxicity associated with the use of antitumor antibiotics. Cardiol. News Opin. Train. 2021;9(1):32–8. (In Russ.)]. doi: 10.33029/2309-1908-2021-9-1-32-38.
- Bovelli D., Plataniotis G., Roila F. Кардиологическая токсичность химиотерапевтических препаратов и заболевания сердца, обусловленные проведением лучевой терапии. Минимальные клинические рекомендации Европейского общества медицинской онкологии. М., 2010. С. 423–33. [Bovelli D., Plataniotis G., Roila F. Cardiac toxicity of chemotherapy drugs and heart disease caused by carrying out radiation therapy Minimum Clinical Guidelines of the European Society for Medical Oncology. M., 2010. Р. 423–33. (In Russ.)].
- Perez I.E., Taveras A.S., Hernandez G.A., Sancassani R. Cancer therapyrelated cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445.
- Kremer L.C., van der Pal H.J., Offringa M., et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systemic review. Ann Oncol. 2002;13:819–29. doi: 10.1093/annonc/ mdf167.
- Chang H.M., Moudgil R., Scarabelli T., et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017;70(20):2536–51. doi: 10.1016 / j. jacc. 2017.09.1096.
- Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, and branch of the European Society of ФВ Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63. doi: 10.1016/j.echo.2005.10.005.
- Zamorano J.L., Lancellotti P., Rodriguez Munoz D., et al. Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36):2768–801. doi: 10.1093/eurheartj/ehw21.
- El Ghandour A.H., Sorady M., Azab S., El Rahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev. 2009;1(1):6. doi: 10.4081 / hr.2009.e6.
- Меморандум ESC по лечению онкологических заболеваний и сердечно-сосудистой токсичности, разработанный под эгидой комитета по практике ESC 2016. Российский кардиологический журнал. 2017;22:105–39. [2016 ESC. Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Rus J Cardiol. 2017;22:105–39. (In Russ.)].
- Shevchuk O.O., Posokhova E.A., Sakhno L.A., Nikolaev V.G. Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity. Exp Oncol. 2012;34(4):314–22.
Supplementary files
